CML Partnership 091012c

Article

You are about to leave the Advancing Science, Advancing Care Infosite and view another Ph+ CML resource sponsored by Novartis Pharmaceuticals Corporation.

You are about to leave the Advancing Science, Advancing Care Infosite and view another Ph+ CML resource sponsored by Novartis Pharmaceuticals Corporation.

If you do not wish to leave this site, click Cancel. Or, click OK to continue.

Cancel

OK >

Treatment of Ph+ CML

Advancing Science

Advancing Care

Future goals for Ph+ CML patients are being shaped by an actively evolving paradigm.

Stay up to date with these interactive assets.

Explore the evolution
of Ph+ CML care

Find out more about early
therapies, important milestones,
and the new era of advanced care

Learn more >

A guide to read and interpret IS RQ-PCR reports

Learn how IS RQ-PCR results track progress and inform treatment decisions

The importance of the International Scale for RQ-PCR

A deeper look at why the International Scale is used to standardize results

Watch a new video on Ph+ CML care

The mechanism of the disease provides a crucial learning for treating Ph+ CML

  • Learn More >

Maecenas non auctor est. Aliquam erat

Donec convallis arcu id purus gravida volutpat consectetur sit amet nisi. Nulla in massa.

  • Learn More >

Proin egestas tellus sit amet mi

Donec convallis arcu id purus gravida volutpat consectetur sit amet nisi. Nulla in massa.

  • Learn More >

Curabitur nisi est, consectetur eu mollis

Donec convallis arcu id purus gravida volutpat consectetur sit amet nisi. Nulla in massa.

  • Learn More >

For information about a free trial of IS RQ-PCR, call MolecularMD at 877-459-4979 or
Genoptix at 800-755-1605 and ask about GET RQ-PCR NOW.

To learn more about Ph+ CML treatment options, click here.

Glossary

AP=accelerated phase. BC=blast crisis. BCR-ABL=breakpoint cluster region-abelson. Ph+ CML=Philadelphia chromosome-positive chronic myeloid leukemia. CBC=complete blood count. CHR=complete hematologic response. mCyR=major cytogenic response. PCyR=partial cytogenetic response. CCyR=complete cytogenetic response. FISH=fluorescence in situ hybridization. ELN=European Leukemia Net. MMR=major molecular response. MR=molecular response. MRD=minimal residual disease. NCCN=National Comprehensive Cancer Network. IS=International Scale. RQ-PCR=real-time quantitative polymerase chain reaction. TKI=tyrosine kinase inhibitor.

Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080 © 2012 Novartis 08/12 T-CDE-1047709

Recent Videos
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Brett L. Ecker, MD, discusses the importance of multidisciplinary collaboration in improving patient outcomes in neuroendocrine tumors.
2 experts are featured in this series.
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Related Content
A computational linguistics model designed to locate pancreatic cysts that started to locate pancreatic cancer has the potential to lead to more efficient treatment.

AI Software Learns to Identify Pancreatic Cancer Vs Cysts

Russell C. Langan, MD
November 26th 2024
Article

A computational linguistics model designed to locate pancreatic cysts that started to locate pancreatic cancer has the potential to lead to more efficient treatment.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

Tanios S. Bekaii-Saab, MD, FACP
November 25th 2024
Podcast

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

For patients with KRAS-mutated colorectal cancer, onvansertib plus FOLFIRI/bevacizumab was effective in those who had not received prior bevacizumab.

Onvansertib Combo Shows Significant Efficacy in KRAS+ Colorectal Cancer

Tim Cortese
November 26th 2024
Article

For patients with KRAS-mutated colorectal cancer, onvansertib plus FOLFIRI/bevacizumab was effective in those who had not received prior bevacizumab.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

A computational linguistics model has mitigated disparities in surveillance of the pancreas that primarily affected racial and ethnic minorities.

Bridging Racial and Ethnic Minority Disparities in Pancreatic Cyst Surveillance

Russell C. Langan, MD
November 25th 2024
Article

A computational linguistics model has mitigated disparities in surveillance of the pancreas that primarily affected racial and ethnic minorities.

Site Logo

SPM AE Incidence After CAR T-Cell Therapy in Lymphoma and Myeloma

American Society for Transplantation and Cellular Therapy
November 25th 2024
Article

Findings from the Phase 3 AURIGA trial support the use of lenalidomide plus daratumumab vs lenalidomide alone as post-transplant maintenance therapy for patients with newly diagnosed multiple myeloma.